Luciferase Quantum Dotting

Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase under the control of a CMV promoter.

Description: Adeno-Associated Virus serotype 2 (AAV2) is the best characterized AAV serotype. Nearly all recombinant AAV serotypes utilize the AAV2 inverted terminal repeats (ITRs). AAV2 requires the expression of Heparan Sulfate Proteoglycan (HSPG) on the surface of host for cells for binding and internalization. Of nearly all the discovered AAV serotypes, AAV2 has the best transduction efficiency in cell culture and is the best tool for in vitro studies._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase under the control of a CMV promoter.

Description: Adeno-Associated Virus Serotype 3 (AAV3) shares 82% sequence homology with AAV2, and like AAV2, requires the Heparan Sulfate Proteoglycan (HSPG) receptor for cell attachment. AAV3 vectors transduce human liver cancer cells extremely efficiently because AAV3 utilizes the human Hepatocyte Growth Factor Receptor (hHGFR) as a co-receptor for viral entry, which is highly expressed in these cells. Both the extracellular and intracellular kinase domains of hHGFR are required for AAV3-mediated transgene expression._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

Description: Adeno-Associated Virus Serotype 5 (AAV5) differs from other parvovirus serotypes according to serological and DNA hybridization data, and AAV5 also uses different inverted terminal repeats (ITRs) compared to other AAV serotypes. AAV5 is the most efficient vector for transducing sensory neurons and is effective at mediating gene transfer into human and murine airway epithelia. In addition, AAV5 vectors show a higher tropism for both mouse and human dendritic cells than AAV1, AAV2, AAV7, or AAV8._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

Description: Adeno-Associated Virus serotype 6 (AAV6) appears to be related to AAV1 by sequence analysis and shows the best transduction efficiency in pancreatic beta-cells compared to other AAV serotypes. AAV6 vectors are also particularly effective in the transduction of human prostate, breast, and liver cancer cells._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

Description: Adeno-Associated Virus serotype 8 (AAV8) was isolated from rhesus monkey tissue, and the AAV8 rep and cap nucleotide sequences have 88% homology with AAV7 and 82% with AAV2. AAV8 exhibits greater transduction efficiency in the liver than other AAV serotypes. AAV8 and 9 have recently been used to correct disease-causing mutations and improve muscle function in mouse models of Duchenne muscular dystrophy._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

Description: Adeno-Associated Virus serotype 9 (AAV9) is one of the most promising serotypes for gene therapy applications. AAV9 transduces a wide range of tissue types, including cardiac and skeletal muscle, liver, pancreas, and eye tissue. AAV8 and AAV9 have recently been used to correct disease-causing mutations and improve muscle function in mouse models of Duchenne muscular dystrophy. AAV9 has significantly lower seroprevalence in the human population than other AAV serotypes, making AAV9 a desirable candidate for therapeutic applications.         _x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase gene under the control of a CMV promoter. AAV transduction efficiency can easily be verified by measurement of luciferase activity.

Description: Goat polyclonal Luciferase antibody (biotin) conjugated

Description: Affinity purified Goat polyclonal Luciferase antibody (FITC)

Description: Rabbit polyclonal Luciferase antibody (Biotin)